Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Preclinical investigation continues for recAP in kidney injury
November 2015
SHARING OPTIONS:

BUNNIK, The Netherlands—Biopharmaceutical company AM-Pharma B.V. recently had two papers published on recombinant human Alkaline Phosphatase (recAP) for the potential treatment of acute kidney injury, which appeared in the British Journal of Pharmacology and the International Journal of Pharmaceutics. The first paper details how in-vitro models were used to show how recAP attenuated lipopolysaccharide (LPS)-induced and adenosine triphosphate (ATP)-mediated inflammation in human peritubular epithelial cells (kidney barrier cells), helping the authors conclude that its mechanism of action in the model likely results from its dephosphorylating enzymatic activity of LPS and ATP. The second paper looked at biodistribution of recAP in rat and minipig models and found the liver to be the primary site of accumulation. Pharmacokinetic studies measured plasma concentrations of recAP and found that it displays a linear-dose exposure relationship and clearance in a biphasic manner.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.